Tirzepatide, an injection medication already approved by the Food and Drug Administration (FDA) to treat Type 2 diabetes, is likely to receive FDA approval for another indication — weight loss — later ...

In patients with type 2 diabetes and chronic kidney disease (CKD), semaglutide drastically reduces the risk of major kidney disease events, MACE, and all-cause death while also slowing down loss of ...

A new and expensive trend to losing weight has emerged, and some notable figures are jumping on the bandwagon. The use of certain diabetic medications – including a drug made by Novo Nordisk — to shed ...

Injected medications that treat diabetes and obesity increase the risk of a rare but serious side effect: stomach paralysis, according to new data on the real-world use of the drugs. At least three ...